Wolverine Trading, LLC Apellis Pharmaceuticals, Inc. Call Options Transaction History

Wolverine Trading, LLC

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$28.84 - $41.15 $475,860 - $678,975	16,500 Added 67.62%	40,900 $1.18 Million
Q2 2024 Aug 14, 2024	BUY	$38.07 - $59.71 $365,472 - $573,216	9,600 Added 64.86%	24,400 $935,000
Q1 2024 May 15, 2024	SELL	$55.39 - $72.47 $1.09 Million - $1.43 Million	-19,700 Reduced 57.1%	14,800 $869,000
Q4 2023 Feb 14, 2024	SELL	$37.14 - $64.82 $248,838 - $434,293	-6,700 Reduced 16.26%	34,500 $2.07 Million
Q3 2023 Nov 15, 2023	BUY	$23.65 - $89.22 $560,505 - $2.11 Million	23,700 Added 135.43%	41,200 $1.57 Million
Q2 2023 Aug 23, 2023	BUY	$76.68 - $93.31 $291,384 - $354,578	3,800 Added 27.74%	17,500 $1.59 Million
Q1 2023 May 15, 2023	BUY	$46.59 - $66.96 $638,283 - $917,351	13,700 New	13,700 $904,000
Q2 2022 Aug 15, 2022	SELL	$35.07 - $59.21 $883,764 - $1.49 Million	-25,200 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$35.46 - $54.12 $553,176 - $844,272	15,600 Added 162.5%	25,200 $1.25 Million
Q4 2021 Feb 14, 2022	SELL	$30.74 - $49.16 $774,648 - $1.24 Million	-25,200 Reduced 72.41%	9,600 $460,000
Q3 2021 Nov 12, 2021	BUY	$31.4 - $69.84 $1.09 Million - $2.43 Million	34,800 New	34,800 $1.18 Million

309

115M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.58B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Wolverine Trading, LLC with notifications on news.